CERo Therapeutics Presents Data at Society for [Conference Name]
Summary of the CERo Therapeutics Facts:
This text details promising preclinical and clinical advancement of CER-1236, an investigational T cell therapy by CERo Therapeutics for treating certain blood cancers. Here’s a breakdown:
Key Highlights:
* CER-1236 & its Mechanism: CER-1236 is a T cell product engineered to target the TIM-4 ligand. It’s designed to be more durable and resist exhaustion compared to customary T cell stimulation methods (CD3/CD28). CERo calls these “Chimeric Engulfment Receptor T cells” (“CER-T”) which utilize both traditional T cell killing and engulfment of cancer cells.
* Preclinical Data: Showed sustained T cell expansion and robust cytokine response with CER-1236, unlike the exhaustion seen with standard stimulation. This data was presented at the SITC conference.
* Phase 1 Trial: A first-in-human, multi-center Phase 1/1b study is underway, evaluating CER-1236 in patients with:
* Relapsed/Refractory Acute Myeloid Leukemia (AML)
* AML in remission with measurable residual disease
* Newly diagnosed AML/MDS with TP53 mutations
* trial Focus: The trial is designed to assess safety (primary outcome) and preliminary efficacy (ORR, CR, cCR, MRD) and pharmacokinetics (PK). it’s currently in the dose escalation phase.
* CERo’s Approach: CERo focuses on engineering T cells to combine innate and adaptive immunity for more extensive tumor targeting. They believe CER-T cells could be more effective than current CAR-T therapies and possibly work on both blood cancers and solid tumors.
* CEO Statement: Chris Ehrlich believes the preclinical data supports observations from the ongoing Phase 1 trial.
In essence, CERo is developing a novel T cell therapy with a unique mechanism of action, and early data suggests it might very well be a promising treatment option for AML and other blood cancers.